The US FDA (Food and Drug Administration) has granted IND (investigational new drug) application clearance for Memgen’s MEM-288, their cancer immunotherapy treatment for patients with multiple solid tumors. Following this announcement, Memgen, a clinical-stage biopharmaceutical company, stated that they aim to screen patients by end of 2021 through an open-label, dose escalation Phase 1 first-in-human clinical study. In this study, Memgen hopes to explore the efficacy and tolerability, as well as the anti-tumor impact of the drug, MEM-288. Memgen aims to treat patient who currently do not respond to alternative therapies.
Read more here.